ClinicalTrials.gg
Sign In
CompletedNCT05827328Updated Jul 18, 2023

Explore the Optimal Surgical Timing for Lung Surgery and Mediastinal Surgery After COVID-19 Infection

An observational study in Thoracic Diseases and Thoracic Surgery, sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Completed at 6 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Exploring the optimal interval time in patients with the clinical diagnosis of lung cancer or mediastinal tumors indicated for thoracic surgeries after SARS-CoV-2 infection by comparing 30-day mortality and 30-day morbidity.

02

Conditions studied

  • Thoracic Diseases
  • Thoracic Surgery

Browse trials for

03

In context

Thoracic Diseases

71 studies on the registry are indexed under Thoracic Diseases; 14 are open to participants now.

This study's enrollment of 2,000 is above the median of 122 across 19 observational studies indexed under Thoracic Diseases.

Browse Thoracic Diseases studies →

Lead sponsor

Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 157 studies on the registry; 94 are open to participants now.

Browse Shanghai Pulmonary Hospital, Shanghai, China studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who undergo thoracic surgery for the clinical diagnosis of lung cancer or mediastinal tumors with or without SARS-CoV-2 infection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient has fully understood the nature of this study and voluntarily agreed to participate by signing an informed consent form.
  2. Participants of any gender between the ages of 18 and 85 are eligible.
  3. Preoperative imaging evaluation +/- biopsies indicates that the patient has resectable lung cancer or mediastinal tumors without distant metastasis.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously undergone lung surgery;
  2. Patients previously infected with SARS-CoV-2 more than 6 months before thoracic surgery;
  3. Patients who did not receive Chest computed tomography (CT) at admission or within 7 days before surgery, or whose Chest CT at admission suggests pneumonia or current infection with SARS-CoV-2 (confirmed by routine laboratory tests as positive nucleic acid in admission or on the day of surgery);
  4. The elapsed time from SARS-CoV-2 diagnosis to surgery is within 4 weeks;
  5. Local unresectable lesions or distant metastases are found intraoperatively.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients eligible for lung surgery or mediastinal surgery

    Patients with or without SARS-CoV-2 infection eligible for lung surgery or mediastinal surgery

    Other: Observation

Interventions

  • OtherObservation

    Observe the 30-day mortality and 30-day morbidity.

06

What researchers measure

Primary outcomes

  1. The incidence of perioperative mortality

    30-day mortality after surgery

    Time frame: 30 days after surgery

Secondary outcomes

  1. The incidence of perioperative complications

    30-day morbidity after surgery

    Time frame: 30 days after surgery

07

Study locations

6 sites
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • Anhui Chest Hospital
    Shanghai, China
  • Anqing Municipal Hospital
    Shanghai, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • The First Affiliated Hospital of Anhui Medical University
    Shanghai, China
  • Wuhan University Renmin Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05827328
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Responsible party
Peng Zhang (Professor, Shanghai Pulmonary Hospital, Shanghai, China) — Principal investigator
First posted
Apr 25, 2023
Start date
Jan 29, 2023
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Jul 18, 2023

Study contacts

Peng Zhang
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thoracic Diseases →

Other studies from this sponsor

Shanghai Pulmonary Hospital, Shanghai, China →

Start the discussion